Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

This study is testing an experimental HIV vaccine booster regimen — combining a vaccine component (CD40.HIVRI.Env, also called VRIPRO) with an immune-boosting adjuvant (Hiltonol / Poly-ICLC) — in adults who previously participated in the HVTN 706 HIV vaccine trial, to see if an additional dose or series can strengthen or renew immune responses against HIV. **You may be eligible if...** - You previously participated in the HVTN 706 study (either as a vaccine or placebo recipient; vaccine recipients must have completed all 4 vaccinations) - You are between 18 and 60 years old - You are in good general health - You agree to HIV prevention counseling throughout the study - Your blood count (hemoglobin) meets the minimum required level **You may NOT be eligible if...** - You did not participate in HVTN 706 - You are enrolled in another study of an investigational drug (unless approved by both studies) - You have health conditions that would interfere with safety monitoring - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.